TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $5,122,000 | +220.5% | 68,062 | +14.4% | 0.01% | +250.0% |
| Q1 2022 | $1,598,000 | -47.8% | 59,510 | -7.2% | 0.00% | -50.0% |
| Q4 2021 | $3,060,000 | -30.0% | 64,154 | -2.5% | 0.00% | -33.3% |
| Q3 2021 | $4,369,000 | -12.5% | 65,769 | +2.8% | 0.01% | -14.3% |
| Q2 2021 | $4,993,000 | +21.5% | 63,996 | +47.3% | 0.01% | +16.7% |
| Q1 2021 | $4,110,000 | -28.0% | 43,455 | -7.2% | 0.01% | -25.0% |
| Q4 2020 | $5,705,000 | +59.5% | 46,821 | +14.4% | 0.01% | +33.3% |
| Q3 2020 | $3,577,000 | +30.4% | 40,940 | -3.6% | 0.01% | +20.0% |
| Q2 2020 | $2,744,000 | +68.9% | 42,480 | +16.7% | 0.01% | +66.7% |
| Q1 2020 | $1,625,000 | -22.9% | 36,389 | +7.6% | 0.00% | -25.0% |
| Q4 2019 | $2,108,000 | +733.2% | 33,834 | +402.8% | 0.00% | – |
| Q3 2019 | $253,000 | +6.8% | 6,729 | +15.7% | 0.00% | – |
| Q2 2019 | $237,000 | – | 5,818 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |